DiagnoCure axes French subsidiary Samba
This article was originally published in Clinica
Quebec-based cancer diagnostics company DiagnoCure has announced it will immediately stop funding its Samba Technologies subsidiary, based in Meylan, France. The digital imaging and IT business, which initially partnered with DiagnoCure for the automation of a bladder cancer immunoassay, "is outside of our molecular diagnostics focus", said DiagnoCure president and CEO John Schafer.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.